UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 831

Sortiert nach

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

Lung cancer (Amsterdam, Netherlands), 2024-08, Vol.194, p.107865, Article 107865

2024

Link zum Volltext

Verfügbarkeit prüfen

Exploring the use of circulating tumor DNA for mutational signature analysis

Lung cancer (Amsterdam, Netherlands), 2024-07, Vol.193, p.107844, Article 107844

2024

Link zum Volltext

Verfügbarkeit prüfen

Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC

Lung cancer (Amsterdam, Netherlands), 2024-07, Vol.193, p.107856, Article 107856

2024

Link zum Volltext

Verfügbarkeit prüfen

The Peninsula stage III non-small cell lung cancer audit: assessing the impact of COVID-19 on treatment decisions

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S27-S27

2023

Link zum Volltext

Verfügbarkeit prüfen

ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project

Lung cancer (Amsterdam, Netherlands), 2024-08, Vol.194, p.107860, Article 107860

2024

Link zum Volltext

Verfügbarkeit prüfen

Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis

Lung cancer (Amsterdam, Netherlands), 2021-07, Vol.157, p.147-155

2021

Link zum Volltext

Verfügbarkeit prüfen

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing

Lung cancer (Amsterdam, Netherlands), 2020-10, Vol.148, p.105-112

2020

Link zum Volltext

Verfügbarkeit prüfen

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

Lung cancer (Amsterdam, Netherlands), 2021-01, Vol.151, p.20-24

2021

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2019-12, Vol.138, p.79-87

2019

Link zum Volltext

Verfügbarkeit prüfen

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe

Lung cancer (Amsterdam, Netherlands), 2021-04, Vol.154, p.161-175

2021

Link zum Volltext

Verfügbarkeit prüfen

The evolving role of liquid biopsy in lung cancer

Lung cancer (Amsterdam, Netherlands), 2022-10, Vol.172, p.53-64

2022

Link zum Volltext

Verfügbarkeit prüfen

Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors

Lung cancer (Amsterdam, Netherlands), 2020-12, Vol.150, p.76-82

2020

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Lung cancer (Amsterdam, Netherlands), 2021-02, Vol.152, p.7-14

2021

Link zum Volltext

Verfügbarkeit prüfen

Perioperative targeted therapy for oncogene-driven NSCLC

Lung cancer (Amsterdam, Netherlands), 2022-10, Vol.172, p.160-169

2022

Link zum Volltext

Verfügbarkeit prüfen

Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA

Lung cancer (Amsterdam, Netherlands), 2019-08, Vol.134, p.96-99

2019

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

Lung cancer (Amsterdam, Netherlands), 2020-12, Vol.150, p.114-122

2020

Link zum Volltext

Verfügbarkeit prüfen

Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC

Lung cancer (Amsterdam, Netherlands), 2021-08, Vol.158, p.126-136

2021

Link zum Volltext

Verfügbarkeit prüfen

Galectin-9 in non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2019-10, Vol.136, p.80-85

2019

Link zum Volltext

Verfügbarkeit prüfen

NTRK fusions in lung cancer: From biology to therapy

Lung cancer (Amsterdam, Netherlands), 2021-11, Vol.161, p.108-113

2021

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights

Lung cancer (Amsterdam, Netherlands), 2024-07, Vol.193, p.107848, Article 107848

2024

Link zum Volltext

Verfügbarkeit prüfen

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

Lung cancer (Amsterdam, Netherlands), 2020-09, Vol.147, p.137-142

2020

Link zum Volltext

Verfügbarkeit prüfen

EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment

Lung cancer (Amsterdam, Netherlands), 2024-06, Vol.192, p.107815, Article 107815

2024

Link zum Volltext

Verfügbarkeit prüfen

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in LungAdenocarcinoma Patients

Lung cancer (Auckland), 2020-02, Vol.11, p.19-25

2020

Link zum Volltext

Verfügbarkeit prüfen

KRAS-Mutant non-small cell lung cancer: From biology to therapy

Lung cancer (Amsterdam, Netherlands), 2018-10, Vol.124, p.53-64

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 831

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieLung Cancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(829)
Mit Volltextzugriff
(827)

Publikationsform

Artikel
(831)

Sprache

Erscheinungsjahr

n.n

Thema

Oncology
(769)
Life Sciences & Biomedicine
(765)
Science & Technology
(765)
Respiratory System
(737)
Humans
(653)
Nsclc
(582)
Female
(411)
Male
(411)
Biological And Medical Sciences
(384)
Medical Sciences
(384)
Pneumology
(364)
Lung Neoplasms - Pathology
(362)
Aged
(361)
Middle Aged
(360)
Tumors Of The Respiratory System And Mediastinum
(360)
Hematology, Oncology And Palliative Medicine
(357)
Pulmonary/respiratory
(357)
Lung Neoplasms - Drug Therapy
(353)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(347)
Carcinoma, Non-Small-Cell Lung - Pathology
(330)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ingenta
(828)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(799)
Elsevier ScienceDirect Journals Complete
(799)
MEDLINE
(656)
IngentaConnect Journals
(390)
EZB Electronic Journals Library
(30)
Taylor & Francis Journals Auto-Holdings Collection
(30)
SpringerLink Series
(2)

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

Exploring the use of circulating tumor DNA for mutational signature analysis

Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC

The Peninsula stage III non-small cell lung cancer audit: assessing the impact of COVID-19 on treatment decisions

ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project

Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe

The evolving role of liquid biopsy in lung cancer

Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Perioperative targeted therapy for oncogene-driven NSCLC

Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC

Galectin-9 in non-small cell lung cancer

NTRK fusions in lung cancer: From biology to therapy

Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in LungAdenocarcinoma Patients

Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection

KRAS-Mutant non-small cell lung cancer: From biology to therapy

Aktive Filter

Suchergebnisse filtern